e-learning
resources
Milan 2017
Sunday, 10.09.2017
Rare diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Long-term outcome of 53 patients with anti-Jo-1 antibody-positive interstitial lung disease
T. Nakanishi (Tenri, Japan)
Source:
International Congress 2017 – Rare diseases
Session:
Rare diseases
Session type:
Poster Discussion
Number:
1515
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Nakanishi (Tenri, Japan). Long-term outcome of 53 patients with anti-Jo-1 antibody-positive interstitial lung disease. 1515
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Management of severe community acquired pneumonia – ERS guidelines
Panel discussion on genetics in pulmonary fibrosis
Related content which might interest you:
Nine cases of interstitial lung disease associated with anti-CADM140 antibody positive dermatomyositis
Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Year: 2012
Interstitial lung disease with ANCA-associated vasculitis (AAV-ILD): Clinical features and survival compared to patients with ILD associated with systemic sclerosis and IPF
Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key
Year: 2020
Interstitial lung disease (ILD) in patients with polymyositis/dermatomyositis (PM/DM): clinical features and response to treatment in 6 cases
Source: Eur Respir J 2001; 18: Suppl. 33, 528s
Year: 2001
The prevalence and subtypes of interstitial lung disease in polymyositis and dermatomyositis patients
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Survival predictors in a cohort of patients with idiopathic pulmonary fibrosis biopsy-proven
Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV
Year: 2012
Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients
Source: Breathe, 16 (1) 190321; 10.1183/20734735.0321-2019
Year: 2020
Clinico-laboratory characteristics of patients with interstitial lung disease (ILD) in polymyositis-dermatomyositis (PM/DM)
Source: Eur Respir J 2003; 22: Suppl. 45, 46s
Year: 2003
Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody
Source: Eur Respir Rev 2015; 24: 370-372
Year: 2015
Clinical features and CT findings of anti-Jo-1 antibody positive interstitial lung disease with or without polymyositis and dermatomyositis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Predictors of progression in systemic sclerosis patients with interstitial lung disease
Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019
Year: 2020
Clinical and pathological findings of patients with interstitial lung diseases associated with antisynthetase other than Jo-1 antibodies
Source: Eur Respir J 2005; 26: Suppl. 49, 541s
Year: 2005
Charactaristics and prognosis of autoimmune antibody-positive patients of idiopathic pulmonary arterial hypertension
Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond
Year: 2021
Overall survival is significantly higher in sarcoidosis than in IPF patients after lung transplantation
Source: Annual Congress 2013 –Clinical studies in lung transplantation
Year: 2013
Evaluation of 76 patients with diffuse paranchimal lung disease
Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease
Year: 2007
Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis
Source: ERJ Open Res, 4 (1) 00111-2016; 10.1183/23120541.00111-2016
Year: 2018
Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry
Source: ERJ Open Res, 5 (3) 00170-2018; 10.1183/23120541.00170-2018
Year: 2019
Difference of the clinical characteristics and outcome between interstitial lung disease with dermatomyositis and idiopathic interstitial pneumonia
Source: International Congress 2017 – Lung function testing
Year: 2017
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Source: International Congress 2016 – IPF treatment I
Year: 2016
Clinical characteristics of 30 patients with interstitial pneumonia associated with anti-aminoacyl-tRNA-synthetase antibodies
Source: International Congress 2016 – Connective tissue disorders
Year: 2016
Clinical significance of autoantibody screening in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept